Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2023-04-03 | 2022-11-08 |
| Drug Identification Number | 02244622 | 02244622 |
| Brand name | MILRINONE LACTATE INJECTION, USP | MILRINONE LACTATE INJECTION, USP |
| Common or Proper name | MILRINONE LACTATE INJECTION, USP | MILRINONE LACTATE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | MILRINONE | MILRINONE |
| Strength(s) | 1MG | 1MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10 mL | 10 mL |
| ATC code | C01CE | C01CE |
| ATC description | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2022-11-01 | 2022-11-01 |
| Actual start date | 2022-11-01 | 2022-11-01 |
| Estimated end date | 2023-03-31 | 2023-03-01 |
| Actual end date | 2023-03-31 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Effective February 1, 2023, allocations to cover 100% of historical monthly demand of 10 mL and 100% of historical monthly demand of 20 mL at a 2:1 ratio. Please see communication for further details. | Product is on 100% allocation. |
| Health Canada comments |